| 去势难治性前列腺癌分子预后标志物研究进展 |
| |
| 引用本文： | 王海涛,孟斌. 去势难治性前列腺癌分子预后标志物研究进展[J]. 中国肿瘤临床, 2014, 41(15): 1003-1006. DOI: 10.3969/j.issn.1000-8179.20140605 |
| |
| 作者姓名： | 王海涛 孟斌 |
| |
| 作者单位： | ①.天津医科大学肿瘤医院介入治疗科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室 |
| |
| 摘 要： | 前列腺癌是老年男性常见的恶性肿瘤,内分泌治疗虽可使大多数患者的病情得到控制和改善,但在经过一段时间的缓解后,绝大多数患者会发展为预后极差的去势难治性前列腺癌（CRPC）。对CRPC患者如何实施个体化治疗,以最小的不良反应和最大的获益来延长生存已成为临床工作者亟待解决的难题。目前临床上采用的分级分期方法很难准确预测具有复杂生物学行为的CRPC患者的预后。近年许多肿瘤标志物相继被发现并用于CRPC患者的预后判断,本文对影响CRPC预后的分子标志物做一综述。
|
| 关 键 词： | 去势难治性前列腺癌 分子标志物 预后 个体化治疗 |
| 收稿时间： | 2014-04-14 |
Progress in molecular prognostic biomarkers of castration-resistant prostate cancer |
| |
| Affiliation: | ①.Department of Interventional Therapy; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China②.Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China |
| |
| Abstract: | Prostate cancer is one of the most common malignant tumors among males, and nearly all patients will inevitably develop castration-resistant prostate cancer (CRPC). The prognosis of CRPC patients is very poor. How to implement the individualized treatment plan with minimal side effects and optimum benefit as well as how to prolong the patients' lives have recently become important issues. Current staging and grading systems fail to provide accurate prognoses of most CRPC, which have complicated biological behaviors. Over the past few years, a host of tumor molecular markers have been discovered and can provide prognostic information for CRPC. This review summarizes the molecular prognostic biomarkers that affect the prognosis of CRPC. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
